CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 240 enrolled
Drug / intervention
Vitamin D +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04449718
NCT04449718N/ACompleted
CompareCT.gov

Vitamin D Supplementation in Patients With COVID-19: A Randomized, Double-blind, Placebo-controlled Trial

University of Sao Paulo·interventional·Posted Jun 29, 2020·Updated Nov 17, 2020

In Brief

A clinical study evaluating Vitamin D and Placebo for COVID-19. Completed, enrolled 240 participants across 1 site.

Detailed Summary

Coronavirus disease 2019 (COVID-19) was declared an emergency public health problem by the World Health Organization (WHO) in March 2020. Since then, several initiatives by the medical and scientific community have sought alternatives to treat infected individuals, as well as identifying risk or protective factors for the contamination and prognosis of patients. In this perspective, vitamin D supplementation can improve some important outcomes in critically ill patients, being considered a potent immunomodulatory agent. Vitamin D deficiency is a common outcome in critically ill patients, thus making it a modifiable risk factor with great potential for reducing hospital stay and intensive care and mortality. The investigators speculate that vitamin D supplementation could have therapeutic effects in patients with COVID-19.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesBrazil
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJun 29, 2020
Enrollment StartJun 1, 2020
Primary CompletionOct 7, 2020
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 6.0 years ago

Interventions

Vitamin Ddietary

200,000 IU on admission

Placebodietary

200,000 IU on admission